THE ONLY BIOSYNTHETIC SCAFFOLD WITH ELECTROSPUN MICROFIBER CONSTRUCTION
• Proven to support cell activation, retention, and proliferation 1
• Superior handling characteristics 2
• Optimal fit and fill:
- Elastic characteristics of ReBOSSIS result in 54% compression recovery
- Maintains integrity during and after placement
ReBOSSIS, manufactured and distributed by ORTHOReBIRTH USA, is an exciting addition to the world of biosynthetic bone scaffolding materials. This product features the handling characteristics of cotton, and enhances bone-to-graft interface. Its fibrous nature allows for easier handling and it stays where it’s placed, even after hydration. See below to learn more about this signature offering from ORTHOReBIRTH USA.
ReBOSSIS is the only biosynthetic bone scaffolding product with the handling and hydrophilic characteristics of cotton. Composed of β-TCP, CaCO3, silicon, and PLLA, the special formula in ReBOSSIS contains1% silicon by weight, which is comparable to the level found in natural bone.
The interconnected networks of microporous fibers are created by ORTHOReBIRTH USA’s unique, proprietary manufacturing process that transforms the composite materials into a biodegradable scaffold. ReBOSSIS is particularly effective because it absorbs and retains bioactive fluids, thereby enhancing its osteoinductive capabilities.
Indications for Use
ReBossis is intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseaous defects from traumatic injury to the bone. Rebossis is indicated to be packed gently into bony voids or gaps of the skeletal systems (extremeties and pelvis).
ReBOSSIS, produced and distributed by ORTHOReBIRTH USA, has undergone extensive study in laboratory settings and animal models. Please download and read the white paper on this product to read key findings related to its use in these studies.
The downloadable technical brochure below provides the fine details about ReBOSSIS. Please review this informational pamphlet to learn about the clinical capabilities of this product.
1 Based on results of 2017 studies carried out at the Cleveland Clinic and the Orthopedic Stem Cell Research Lab – Board of Governors Regenerative Medicine Institute, Cedars-Sinai | 2 Based on user survey responses